Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
44.25
+0.04 (0.09%)
At close: Feb 11, 2026, 4:00 PM EST
44.94
+0.69 (1.56%)
After-hours: Feb 11, 2026, 7:59 PM EST
Royalty Pharma Revenue
In the year 2025, Royalty Pharma had annual revenue of $2.38B with 5.06% growth. Royalty Pharma had revenue of $621.99M in the quarter ending December 31, 2025, with 4.78% growth.
Revenue (ttm)
$2.38B
Revenue Growth
+5.06%
P/S Ratio
7.98
Revenue / Employee
$23,780,000
Employees
100
Market Cap
25.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.38B | 114.62M | 5.06% |
| Dec 31, 2024 | 2.26B | -90.98M | -3.86% |
| Dec 31, 2023 | 2.35B | 117.34M | 5.24% |
| Dec 31, 2022 | 2.24B | -52.25M | -2.28% |
| Dec 31, 2021 | 2.29B | 167.11M | 7.87% |
| Dec 31, 2020 | 2.12B | 308.10M | 16.98% |
| Dec 31, 2019 | 1.81B | 19.36M | 1.08% |
| Dec 31, 2018 | 1.79B | 196.96M | 12.33% |
| Dec 31, 2017 | 1.60B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.14B |
| BeOne Medicines AG | 4.97B |
| Genmab | 3.85B |
| BioNTech SE | 3.70B |
| Alnylam Pharmaceuticals | 3.21B |
| Moderna | 2.23B |
| Ionis Pharmaceuticals | 966.96M |
| Insmed | 447.02M |
RPRX News
- 4 hours ago - Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 14 hours ago - Royalty Pharma Reports Q4 and Full Year 2025 Results - GlobeNewsWire
- 22 days ago - Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - GlobeNewsWire
- 4 weeks ago - Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug - Benzinga
- 4 weeks ago - Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo - GlobeNewsWire
- 4 weeks ago - Royalty Pharma Announces Dividend Increase - GlobeNewsWire